Sialix, Inc., a Cambridge, Massachusetts-based biotechnology company developing products for the treatment and prevention of cancer, closed a $1.2m tranche of an angel-led financing.
Backers included Boston Harbor Angels, Mass Medic Angels, Launchpad Angels, Maine Angels, Beacon Angels and Desert Angels (Tuscon, AZ) as well as other undisclosed individuals.
The company intends to use the funds to advance its products.
Led by Jeff Behrens, CEO, Sialix uses a proprietary platform to develop therapeutic antibodies targeting glycan alternations in cancer. In 2012, the company signed a partnership agreement with Momenta Pharmaceuticals and in early 2013 entered the Janssen Labs biotechnology incubator in San Diego.
Sialix has offices in Cambridge, MA and a laboratory in San Diego, CA.
FinSMEs
05/02/2014